Clinical Trial Update: Vascepa to Accelerate Lipoprotein Uptake and Elimination [Phase 1]

View source ↗

Summary

Phase 1 trial update on Vascepa accelerating lipoprotein uptake and elimination; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Lipid Disorder
• Triglycerides High

Drugs mentioned

• Vascepa (icosapent ethyl)

Snippet

Sponsor: University of Pennsylvania | Conditions: Lipid Disorder, Triglycerides High | Phase 1 | Status: COMPLETED | Results posted: 2021-11-11